Skip to main content
banner image
No data available.
Please log in to see this content.
You have no subscription access to this content.
No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.
The full text of this article is not currently available.
1.B. J. Allen, E. Bezak, and L. G. Marcu, “Quo vadis radiotherapy? Technological advances and the rising problems in cancer management,” BioMed Res. Int. 749203 (2013).
2.J. G. Jurcic et al., “Targeted alpha particle immunotherapy for myeloid leukemia,” Blood 100, 12331239 (2002), see
3.C. Kratochwil et al., “213Bi − DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: A first-in-human experience,” Eur. J. Nucl. Med. Mol. Imaging 41(11), 21062119 (2014).
4.B. J. Allen et al., “Intralesional targeted alpha therapy for metastatic melanoma,” Cancer Biol. Ther. 4, 13181324 (2005).
5.C. Raja et al., “Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma,” Cancer Biol. Ther. 6, 846852 (2007).
6.B. J. Allen et al., “Analysis of patient survival in a phase 1 trial of systemic targeted alpha therapy for metastatic melanoma,” Immunotherapy 3, 10411050 (2011).
7.S. Tagawa et al., “Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody J591 in men with metastatic castration-resistant prostate cancer,” Front. Oncol. 3, 214 (6 pages) (2013).
8.J. Elgqvist, “Hot-topic issues. Targeted alpha therapy,” Curr. Radiopharm. 3&4, 176342 (2011), and papers therein.
9.J. Elgqvist, S. Frost, J.-P. Pouget, and P. Albertsson, “Potential and hurdles of targeted alpha therapy – Clinical trials and beyond,” Front. Oncol. 3, Article 324 (9 pages) (2014).
10.D. A. Mulford, D. A. Scheinberg, and J. G. Jurcic, “The promise of targeted α-particle therapy,” J. Nucl. Med. 46, 199S204S(2005), see
11.E. B. Holliday and S. J. Frank, “Proton radiation therapy for head and neck cancer: A review of the experience to date,” Int. J. Radiat. Oncol., Biol., Phys. 89, 292302 (2014).
12.T. I. Yock, S. Bhat, J. Szymonifka, B. Y. Yeap, J. Delahaye, S. S. Donaldson, S. M. MacDonald, M. B. Pulsifer, K. S. Hill, T. F. DeLaney, D. Ebb, M. Huang, N. J. Tarbell, P. G. Fisher, and K. A. Kuhlthau, “Quality of life outcomes in proton and photon treated pediatric brain tumor survivors,” Radiother. Oncol. 113, 8994 (2014).
13.S. Webb, P. M. Evans, W. Swidell, and J. O. Deasy, “A proof that uniform dose gives the greatest TCP for fixed integral dose in the planning target volume,” Phys. Med. Biol. 39, 20912098 (1994).
14.M. F. Moyers, T. Toth, R. Sadagopan, A. Chvetsov, J. Unkelbach, R. Mohan, D. Lesyna, L. Lin, Z. Li, F. Poenisch, W. Newhauser, S. Vatnitsky, and J. Farr, “Physical uncertainties in the planning and delivery of light ion beam treatments,” AAPM TG202 Report (submitted for publication).
15.E. Klein, T. Zhao, K. Grantham, and S. Goddu, “Routine quality assurance for the MEVION S250 proton system,” Med. Phys. 40(6), 231(1pp.) (2013).
16.H. Jadvar and D. I. Quinn, “Targeted α-particle therapy of bone metastases in prostate cancer,” Clin. Nucl. Med. 38, 966971 (2013).

Data & Media loading...


Article metrics loading...



There is no abstract available for this article.


Full text loading...


Access Key

  • FFree Content
  • OAOpen Access Content
  • SSubscribed Content
  • TFree Trial Content
752b84549af89a08dbdd7fdb8b9568b5 journal.articlezxybnytfddd